Dennis Mauricio1, Burak Zeybek1, Joan Tymon-Rosario1, Justin Harold1, Alessandro D Santin2. 1. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, LSOG Bld. Room 305, 333 Cedar Street, PO Box 208063, New Haven, CT, 06520-8063, USA. 2. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, LSOG Bld. Room 305, 333 Cedar Street, PO Box 208063, New Haven, CT, 06520-8063, USA. alessandro.santin@yale.edu.
Abstract
PURPOSE OF REVIEW: This review aims to summarize the current immunotherapy studies and the potential targeted therapies showing promise in the treatment of cervical cancer. RECENT FINDINGS: There are promising ongoing monotherapy and combination therapy trials using different immune checkpoint inhibitors, poly adenosine diphosphate ribose polymerase inhibitors, tumor angiogenesis inhibitors (i.e., bevacizumab), antibody-drug conjugates, therapeutic vaccines, and tumor-infiltrating T lymphocytes (adoptive immunotherapy). Some of these novel modalities are also being evaluated in combination with standard platinum-based chemotherapy regimen. At this time, pembrolizumab is approved for the treatment of relapsed or metastatic programmed death ligand 1 (PD-L1) positive cervical cancer after frontline chemotherapy treatment. Multiple novel therapeutic modalities are emerging as safe and effective for the treatment of cervical cancer patients. Development and participation in investigative treatments can provide benefit and improve outcomes in cervical cancer.
PURPOSE OF REVIEW: This review aims to summarize the current immunotherapy studies and the potential targeted therapies showing promise in the treatment of cervical cancer. RECENT FINDINGS: There are promising ongoing monotherapy and combination therapy trials using different immune checkpoint inhibitors, poly adenosine diphosphate ribose polymerase inhibitors, tumor angiogenesis inhibitors (i.e., bevacizumab), antibody-drug conjugates, therapeutic vaccines, and tumor-infiltrating T lymphocytes (adoptive immunotherapy). Some of these novel modalities are also being evaluated in combination with standard platinum-based chemotherapy regimen. At this time, pembrolizumab is approved for the treatment of relapsed or metastatic programmed death ligand 1 (PD-L1) positive cervical cancer after frontline chemotherapy treatment. Multiple novel therapeutic modalities are emerging as safe and effective for the treatment of cervical cancer patients. Development and participation in investigative treatments can provide benefit and improve outcomes in cervical cancer.
Authors: Alessandro D Santin; Wei Deng; Michael Frumovitz; Natalia Buza; Stefania Bellone; Warner Huh; Samir Khleif; Heather A Lankes; Elena S Ratner; Roisin E O'Cearbhaill; Amir A Jazaeri; Michael Birrer Journal: Gynecol Oncol Date: 2020-01-07 Impact factor: 5.482
Authors: Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Linda R Duska; Jennifer M Scalici; Sarah M Temkin; Julie K Schwarz; Erin K Crane; Katherine M Moxley; Chad A Hamilton; Stephanie L Wethington; Gina R Petroni; Nikole E Varhegyi; Sheena H Clift; Timothy N J Bullock; Timothy N Showalter Journal: Cancer Date: 2020-09-10 Impact factor: 6.860
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Jyoti Mayadev; Ana T Nunes; Mary Li; Michelle Marcovitz; Mark C Lanasa; Bradley J Monk Journal: Int J Gynecol Cancer Date: 2020-05-23 Impact factor: 3.437
Authors: Claire F Friedman; Alexandra Snyder Charen; Qin Zhou; Michael A Carducci; Alexandre Buckley De Meritens; Bradley R Corr; Siqing Fu; Travis J Hollmann; Alexia Iasonos; Jason A Konner; Panagiotis A Konstantinopoulos; Susan C Modesitt; Elad Sharon; Carol Aghajanian; Dmitriy Zamarin Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751
Authors: Carly A Burmeister; Saif F Khan; Georgia Schäfer; Nomonde Mbatani; Tracey Adams; Jennifer Moodley; Sharon Prince Journal: Tumour Virus Res Date: 2022-04-20